Quick Answer
Protalix BioTherapeutics, Inc. reported R&D Expense of $19.57 million for fiscal year 2025.
Protalix BioTherapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $19.57M | +50.9% |
| 2024 | $12.97M | -24.1% |
| 2023 | $17.09M | -41.8% |
| 2022 | $29.35M | -1.3% |
| 2021 | $29.73M | -22.1% |
| 2020 | $38.17M | -14.5% |
| 2019 | $44.62M | +33.9% |
| 2018 | $33.33M | +3.6% |
| 2017 | $32.17M | +5.8% |
| 2016 | $30.41M | +22.2% |
| 2015 | $24.89M | -9.0% |
| 2014 | $27.35M | -6.4% |
| 2013 | $29.23M | -20.3% |
| 2012 | $36.66M | -3.0% |
| 2011 | $37.82M | +0.3% |
| 2010 | $37.69M | +37.6% |
| 2009 | $27.39M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $4.47M | +49.0% | -25.5% |
| June 30, 2025 | $5.99M | +102.4% | +72.4% |
| March 31, 2025 | $3.48M | +20.4% | +15.9% |
| September 30, 2024 | $3.00M | -18.3% | +1.2% |
| June 30, 2024 | $2.96M | -33.8% | +2.6% |
| March 31, 2024 | $2.89M | -50.6% | -21.3% |
| September 30, 2023 | $3.67M | -50.3% | -18.0% |
| June 30, 2023 | $4.47M | -41.0% | -23.5% |
- Protalix BioTherapeutics, Inc. showed an increase of +50.9% in R&D Expense compared to the prior fiscal year.
- Over the 2009–2025 period, Protalix BioTherapeutics, Inc.’s r&d expense has declined by 28.6% (from $27.39 million to $19.57 million).
- The most recent figure is from Protalix BioTherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: